The high abundance of immunoglobulins (Igs) in the plasma protein corona on poly(lactic-coglycolic) acid (PLGA)-based vascular-targeted carriers (VTCs) has previously been shown to reduce their adhesion to activated endothelial cells (aECs) in human blood flow. However, the relative role of individual Ig classes (e.g., IgG, IgA, and IgM) in causing adhesion reduction remains largely unknown. Here, we characterized the influence of specific Ig classes in prescribing the binding efficiency of PLGA nano-sized VTCs in blood flow. Specifically, we evaluated the flow adhesion to aECs of PLGA VTCs with systematic depletion of various Igs in their corona. Adhesion reduction was largely eliminated for PLGA VTCs when all Igs were removed from the corona. Furthermore, re-addition of IgA or IgM to the Igs-depleted corona reinstated the low adhesion of PLGA VTCs, as evidenced by 40-70% reduction relative to particles with an Igs-deficient corona. However, re-addition of a high concentration of IgG to the Igs-depleted corona did not cause significant adhesion reduction. Overall, the presented results reveal that PLGA VTC adhesion reduction in blood flows is primarily driven by high adsorption of IgA and IgM in the particle corona. Precoating of albumin on PLGA VTCs mitigated the extent of adhesion reduction in plasma for some donors but was largely ineffective in general. Overall, this work may shed light into effective control of protein corona composition, thereby enhancing VTC functionality in vivo for eventual clinical use.
glycol coating (PEG) coating on the particle surface. 11, 13, 14 These observations were attributed to the significant presence of immunoglobulins (Igs) in the corona formed on the NP surface, which prevents adhesive interaction of the targeting ligands with their corresponding cell or surface receptors. 8, [11] [12] [13] [14] However, the precise role of individual Ig protein classes in this process has yet to be studied. Since protein properties vary widely, it is plausible that corona-derived effects are linked to a single or combination of a few proteins with certain features (e.g., large molecular weight, low off-rate, and conformational stability)
rather than an aggregate effect of the complex corona. For instance,
IgG is known to be highly opsonic in nature, and this feature has been linked to its significant presence on NP surface, leading to rapid hepatic uptake and clearance in vivo. 15, 16 This work seeks to evaluate (a) which Ig class(es) in a vascular- here as our prior work demonstrated the high sensitivity of this material to human plasma and due to its ubiquitous use for construction of many drug delivery systems. 17 We investigate the individual impact of IgG, IgA, or IgM since these Ig classes collectively constitute the majority (98%(m/m)) of plasma Ig content and thus are expected to play significant roles in driving PLGA adhesion reduction.
We explored the covalent attachment of albumin to PLGA VTCs given the availability and common use of this dysopsonin protein in increasing circulation time of NPs in the bloodstream by counteracting opsonin (e.g., IgG, complement) adsorption and silencing recognition by the mononuclear phagocytic system (MPS). 7, [18] [19] [20] [21] [22] Finally, we focused on non-PEGylated VTCs to emphasize the effect of the base material (PLGA) in any corona-derived observations, which is expected to offer critical insight into the amplitude of surface modifications required to abate or alter plasma protein adsorption. Despite important strides made with their use to achieve non-fouling NPs, 23 PEG coatings on NPs still cannot completely prevent protein adsorption. 18 Furthermore, the formation of anti-PEG antibodies that is expected to accelerate PEG-NP clearance rate upon re-administration in vivo remains a major limitation. 24 Thus, there is a need for more research to elucidate further the mechanism of protein corona-induced altering of VTCs targeting, which would provide valuable information for the development of novel, NP-based therapeutics.
| MATERIALS A ND METHODS

| Particle size and concentration characterization
Carboxylated, 500 nm PLGA particles were obtained from Phosphorex,
Inc. (Hopkinton, MA). Carboxylated PLGA particles were dispersed in PBS11 containing 1%(wt/vol) bovine serum albumin (BSA) and then washed with PBS. Particles were incubated in 50 mM MES at pH 7 for-20 hr prior to DLS measurement of size distribution (Table 1) , corresponding to the time required for the NeutrAvidin conjugation.
| Biomolecule surface conjugation
Particles were first conjugated with NeutrAvidin via covalent carbodiimide chemistry followed by linkage to biotinylated sialyl-Lewis a (sLe a ) (Glycotech Corporation; Gaithersburg, MD) as described elsewhere. 25 Briefly, 9.1 3 10 9 mm 2 /ml particles were incubated with 5 mg/ml NeutrAvidin in MES buffer for 15 min, followed by addition of an equal volume of 75 mg/ml EDAC. For particles with both albumin and NeutrAvidin attached, human serum albumin (Sigma-Aldrich) was added in a 4:1 ratio with NeutrAvidin during the incubation step. The solution pH was then adjusted to 7.4 and placed on an end-to-end rotator for 20 hr. The conjugation reaction was halted with 7.5 mg glycine/ml, and the protein-coated particles were washed with and re-suspended in 1 ml of PBS. Attachment of the targeting ligand, sLe a , on PLGA particles was performed by suspending NeutrAvidin or NeutrAvidin 1 Albumin particles in 100 mL of biotinylated sLe a (diluted in PBS11 1%(wt/vol) BSA) at a concentration of 0.5-3 mg/ml at a surface area to volume ratio of 1.5 3 10 9 mm 2 /ml for 45 min.
| Quantification of biomolecule surface density
NeutrAvidin density was quantified using an Attune flow cytometer (Applied Biosystems) via staining conjugated particles with biotin-PE for 20 min, followed by washing with PBS11 1%(wt/vol) BSA.
Quantification of the number of NeutrAvidin and sLe a sites on the particle surface was achieved via use of Quantum R-PE MESF or FITC calibration beads (Bangs Laboratories) as previously described. 25 Particle sLe a density (Table 2) was determined via staining with anti-CLA-PE (Miltenyi Biotec; San Diego, CA). Rat-IgM-PE (Fisher Scientific) was used as the isotype control. Albumin surface density was tested in a similar manner via goat-anti-albumin-FITC (human). Particles stained with goat-IgG-FITC at the same concentration served as the isotype control. Table 3 lists the albumin and NeutrAvidin surface densities obtained for PLGA particles in this work. 
| Parallel plate flow chamber assay
Flow adhesion assays were performed on a Nikon TE 2000-S inverted microscope fitted with a digital camera. Circular parallel plate flow chambers (PPFCs) (Glycotech Corporation) containing a straight rectangular channel were used in these assays, as described elsewhere. 11, [25] [26] [27] Briefly, an activated coverslip containing a monolayer of activated HUVEC was vacuum-sealed to the bottom of the flow chamber deck. Flow through the chamber was initiated via a programmable syringe pump. Before the flow assays, particles were incubated in plasma in a similar manner as previously described in Sobczynski and Eniola-Adefeso
12
, with a few key differences. Prior studies with PLGA particles have shown that after 5 min of exposure to 100% (i.e., undiluted) plasma, the extent of the adhesion reduction was saturated with no additional reduction observed up to 60 min incubation time. 11 Since the depletion kits limited the amount of depleted plasma available, incubation of diluted plasma was employed, and particles were incubated for 1 hr (Supporting Information Figure   S1 ). The 1 hr incubation time with 25% plasma was chosen here since similar levels of adhesion reduction were achieved with this condition, as compared to 5 min 100% plasma incubation, 11, 12 BSA and 1.4%(wt/vol) dextran 13, 29 ) medium as previously described.
The hematocrit was fixed to 38%(vol/vol) for all experiments. Particles in RBCs-in-VB were introduced to the flow chamber for 5 min at a shear rate of 200/s. After the flow experiment, the particle adhesion density (#bound/mm 2 ) to HUVEC was obtained by fluorescent imaging along the width of the monolayer at a fixed position from the channel entrance.
| SDS-PAGE
SDS-PAGE was performed using 4-20% Tris-Glycine precast gels from Bio-Rad Laboratories or Life Technologies as previously described in. 12 For the solutions prepared in the SDS-PAGE experiments, conditions were diluted to 2% plasma solution, and therefore the total protein content during loading is expected to be similar across the different conditions. For the gels characterizing the corona proteins stripped from the NP surface, loading was normalized across the different experimental conditions by fixing the total particle surface area (typically 2.54 3 10 8 mm 2 /ml plasma). Furthermore, the same batch of particles exposed to the same amount of plasma was used on a given day for all conditions to reduce any deviations in expected particle concentration due to counting different particle stocks.
| ELISA
Sandwich ELISA was employed for measurement of human plasma IgG, IgA, and IgM concentrations. Clear, 96-well plates were coated with the appropriate antibody at 1-6 mg/ml overnight (50 mL/well). 
| Statistical methods
Data was analyzed using Prism. Data in figures were plotted with standard error and comparisons between adhesion assays were performed using one-way ANOVA with Tukey post-test or unpaired t test with a confidence interval of 99% (a 5 .01). Welch's correlation was used for the t test if appropriate.
| R E S U L T S 3.1 | Assessment of Ig depletion column specificity
It is critical to assess the specificity of the commercially obtained depletion kits employed in this work for the removal of IgG, IgA, and other
Igs from human plasma. Both IgG and IgA in blood plasma are 150 kDa in size, as confirmed via SDS-PAGE of commercially obtained solutions (Supporting Information Figure S2 ). Table 4 However, it is possible that variation in IgG affinity for PLGA across donors also contributes to the observed deviations in particle adhesion between donors in the absence of IgG. As such, SDS-PAGE was performed for NPs incubated in native plasma from donors A, C, and D.
The PLGA corona formed from donor A showed a noticeably heavier adsorption of the 150 kDa Ig band (12-fold increase in intensity)
when compared head-to-head with corona formed from donor C or D plasma (Supporting Information Figure S4 ). Since donors A and C have a similar plasma level of IgG, the high presence of the 150 kDa band in the corona acquired from "A" relative to C plasma suggests that IgG affinity for PLGA also contributes to the significant adhesion recovery observed upon removal of IgG from donor A's plasma.
| Evaluation of how adsorption of specific Ig classes to plasma corona affects PLGA NP adhesion
The lack of a full recovery in the absence of IgG, unlike observed with the deletion of all Igs from above, suggests that other Ig types also play a role in the plasma corona-induced blocking of PLGA NP adhesion.
Since it was not possible to exclusively remove the other main Ig types as performed with IgG, we examined the inverse experiment-total removal of Ig proteins followed by a systematic re-addition of a particular class (IgG, IgA, or IgM) to the PLGA corona. It is important to note
here that solely IgA1 was tested in the ELISA experiments since 80-90%(m/m) of IgA in blood consists of IgA1 (monomeric structure). 31 The composition and concentration of the different Ig solutions used in the re-addition experiments were denoted as follows: "Iso-IgG" (94% (m/m) IgG, 5 mg/ml), "Iso-IgA" (70%(m/m) IgA1, 0.6-0.8 mg/ml) (See Supporting Information Figure S5 ) and "Purified-IgM". Iso-IgA and Purified-IgM were re-added at physiological levels given their relatively pure composition and to best represent the individual impact of these Ig classes on PLGA adhesion reduction in vivo. Physiological concentrations of IgA1 and IgM were based on the ELISA measurements (Supporting Information Figure S6 ). Conversely, a high Iso-IgG concentration (5 mg/ml for 25% plasma solution) was employed in the re-addition experiment to mimic donor A's plasma conditions, where exclusive removal of IgG from the corona resulted in a major, significant increase in adhesion efficiency. Figure 3A shows SDS-PAGE of the various protein solutions in which particle coronae were formed. Figure 3B shows the relative adhesion levels obtained for PLGA NPs incubated in the various solutions characterized in Figure 3A .
Overall, the removal of all Igs plus re-addition of the 160 kDa (IgArich) band corresponds to significant adhesion reduction, 
| Albumin protein attachment to mitigate Iginduced PLGA adhesion reduction
To determine if the Ig corona-induced reduced adhesion efficiency of PLGA particles could be neutralized, we evaluated the flow adhesion of albumin-conjugated PLGA (PLGA 1 Albumin) particles exposed to native plasma and buffer and compared the results to the adhesion of standard PLGA particles (Figure 4 ). On average, there was no significant difference in the extent of adhesion (relative to buffer) between standard PLGA-sLe a and PLGA 1 Albumin-sLe a particles (8,000 sites/mm 2 ) with a native plasma corona when averaged across several donors ( Figure   4A ). However, analysis of the adhesion of standard and albuminconjugated particles between individual donors revealed that the albumin-conjugated particles performed at 54 6 13% higher adhesion efficiency relative to that of the standard PLGA when the coronae were derived from donor C's plasma ( Figure 4B ). Furthermore, an SDS-PAGE gel analysis of the particle corona upon exposure to donor C plasma shows a twofold decrease in intensity of the 150 kDa band (Ig-rich) band for the corona stripped from the albumin-conjugated relative to the standard PLGA particles (intensity normalized to respective particle PBS corona; Supporting Information Figure S7 ). PLGA 1 Albumin particle adhesion was also slightly increased relative to standard PLGA when exposed to donor E (20 6 8% increase); however, this was not significant when tested via one-way ANOVA (p 5 .4620). In the case of -targeted PLGA particles incubated for 1 hr in 25% plasma (native), 25% plasma (Igs-depleted), 25% plasma (Igsdepleted) 1 5 mg/ml Iso-IgG, 0.6-0.8 mg/L Iso-IgA, and 0.2 mg/ml commercial IgM prior to a parallel plate flow chamber assay in RBCsin-VB (38% hematocrit) at 200/s. * 5 p < .01 compared to 25% plasma (native) trial, concentration 1 3 10 6 # particles/ml a viable alternative to invasive surgical procedures and poorly localizing therapies that cause a host of detrimental side effects to patients. 1, 3, 32 Recently, the drug carrier's plasma protein corona has been identified to exert an adverse effect on particle adhesion efficiency. 8, 11, 13, 14 Thus, it is of great interest to the field to determine whether corona-induced adhesion reduction is driven by specific proteins (e.g., size, surface affinity), as this would offer key insight into the intelligent design of highly efficient VTCs. Moreover, a growing body of literature has focused on "exploiting" the protein corona by attracting a high presence of specific protein types into the corona to improve cell targeting and uptake efficiency. 10, [33] [34] [35] [36] The data presented in this study shows that PLGA adhesion Given the high abundance of IgG in plasma and its well-known opsonic nature, it was surprising that the removal of IgG from the corona did not significantly restore adhesion efficiency except one donor-A. We hypothesize that PLGA adhesion was effectively restored when the corona was depleted of donor A's IgG due to this donor having a relatively high plasma IgG concentration ( Figure 2C ) and a seemingly higher affinity for the PLGA corona compared with IgG in other donors (Supporting Information Figure S4 ). As such, we conclude that donor A may simply be an anomaly, especially as the re-addition of iso- Figure S2 ), which may promote a larger steric interference of receptorligand interactions at the particle surface, thereby weakening adhesion kinetics despite its lower plasma and expected corona concentration than IgG, for instance. While IgA has similar molecular weight to IgG, its dominant role in causing PLGA adhesion reduction could be linked to the similarities of this protein's structural features with IgM, such as the short tailpieces of their CH 3 domains bonded to J-chains through disulfide bonds in multimeric forms. 37 Although this work focused on testing monomeric IgA1 due to its abundance in serum, dimeric IgA (like pentameric IgM) is still present in serum and is much larger than IgG and thus may be more likely to disrupt PLGA targeting efficiency at the NP surface. Also, IgM and IgA also possess similar j and k light chains which may contribute to the similar adverse effects on adhesion observed upon adsorption of these Ig classes in the protein corona. 43 It is important to mention that IgD (180 kDa) and IgE (200 kDa) may contribute to some of these observations but it is hypothesized that this is unlikely given their extremely low plasma concentration (2-3 orders of magnitude below physiological IgM level). 44, 45 Last, while fibrinogen and fibronectin are also present at high levels and have a strong influence on cellular adhesion, it is unlikely that a non-specific depletion of these proteins contribute to PLGA particle adhesion recovery with Ig depletion due to the confirmed specificity of the depletion kits use. Moreover, a recent work compared the impact of trial, concentration 1 3 10 6 # particles/ml serum, which is plasma depleted of clotting factors along with fibrinogen and to some extent fibronectin, to plasma and showed the serum acquired corona conferred a stronger adverse effect on PLGA particle adhesion. 12 Thus, it is unlikely that these proteins contribute to the depletion effects reported in this work.
Given the broad use of PLGA for drug delivery applications and prior FDA approval status, strategies to mitigate the Ig-induced reduction in targeted adhesion to the vascular endothelium are of interest.
While PEGylation of NP surfaces has been extensively explored, and shown to reduce protein adsorption, increase circulation time in vivo, and improve adhesion kinetics in blood flow, 46, 47 it is also widely known that PEGylation does not eliminate protein adsorption. Figure S4 ). Thus, it is likely easier for the albuminconjugated NPs to resist IgA adsorption in donor C plasma compared to donor A. Overall, given that albumin was only effective for donor C, other avenues for achieving non-fouling PLGA VTCs still needs to be explored. One possibility may be the use of zwitterionic functionalities on PLGA surfaces, as these materials have shown remarkable promise in eliminating protein adsorption to the particle surface. 53, 54 Though, it remains largely unknown whether these biocompatible coatings will eliminate corona-induced reduced particle adhesion efficiency to HUVEC in the context of the complex, dynamic blood flow environment.
53,55-58
| C O NC LU S I O N S
This study revealed that IgA and IgM proteins primarily drive adhesion reduction of plasma-exposed PLGA NPs. These observations will hopefully shed light into the design methodology of high-efficient VTCs capable of evading corona-induced adhesion reduction in blood flow.
Given previous studies, which have demonstrated the inherent limitations of PEG coatings, it will be of great interest to explore employment of zwitterionic or carbohydrate coatings to achieve high-efficient binding PLGA NPs. Finally, this study is inherently limited given its use of in vitro assays, which fail to capture the added complexity of the in vivo corona. Indeed, future studies have will transition toward probing differential effects of protein corona fouling between in vitro and in vivo exposed particles. LITERATURE CITED
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